Drug Pricing Hospitals Pharmaceutical Companies 
STAT
FEBRUARY 15, 2024
For several years , some of the world’s largest pharmaceutical companies that participate in a U.S. drug discount program overcharged the federal government and numerous hospitals by hundreds of millions of dollars, according to claims made in a recently unsealed lawsuit. and their number has grown over the years.
STAT
MARCH 17, 2025
Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. The agency also maintained Roche disseminated “erroneous information” about using biosimilars in combination therapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 14, 2024
government agency warned Sanofi that it faces sanctions over plans to change the way payments are made to most hospitals participating in a drug discount program, the third time in recent months that a major pharmaceutical company has been threatened with such a step. Continue to STAT+ to read the full story…
STAT
JANUARY 19, 2023
In a bid to blunt competition and address rising drug costs, Sanofi is offering a warranty that will cover the cost for any hospital if a specific medicine fails to work, marking only the second time a major pharmaceutical company has taken such a step.
Pharmaceutical Technology
JANUARY 16, 2023
This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.
Proxsys Rx
JANUARY 10, 2023
Nobody’s ever put it better than the Association of American Medical Colleges (AAMC): “Congress created the 340B Drug Pricing Program in 1992 to protect safety-net hospitals from escalating drug prices by allowing them to purchase outpatient drugs at a discount from manufacturers. percent to 3.5
Pharmaceutical Technology
JANUARY 16, 2023
This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.
Expert insights. Personalized for you.
323 
Let's personalize your content